[Clinico-biological classification of systemic lupus]

Area of Science:

• Immunology
• Rheumatology
• Clinical Medicine

Context:

• Systemic lupus erythematosus (SLE) affects nearly all patients with anti-nuclear and anti-cytoplasmic antibodies.
• Anti-double-stranded DNA (anti-dsDNA) and anti-Sm antibodies are specific but vary in prevalence.
• Clinical manifestations in SLE patients can differ significantly based on antibody profiles.

Purpose:

• To correlate specific clinical manifestations in SLE patients with the presence of distinct autoantibodies.
• To investigate the relationship between anti-U1 RNP, anti-histones, anti-Ro (SS-A), anti-phospholipid, anti-type 5 mitochondrial, and anti-ribosomal antibodies and SLE clinical phenotypes.
• To explore the hypothesis that SLE represents a syndrome rather than a single disease entity.

Summary:

• The study examines the association between various autoantibodies (anti-U1 RNP, anti-histones, anti-Ro (SS-A), anti-phospholipid, anti-type 5 mitochondrial, anti-ribosomal) and specific clinical presentations in patients with systemic lupus erythematosus (SLE).
• While anti-dsDNA antibodies are found in 65-95% and anti-Sm in 7-30% of SLE patients, their correlation with specific clinical features was investigated.
• Findings suggest that the diverse clinical-biological subgroups observed in SLE, based on autoantibody profiles, support the concept of SLE as a syndrome.

Impact:

• Highlights the heterogeneity of SLE, emphasizing the need for personalized treatment approaches based on specific autoantibody profiles.
• Provides insights into the complex interplay between immunological markers and clinical phenotypes in SLE.
• Contributes to the understanding of SLE as a multifactorial syndrome, potentially guiding future diagnostic and therapeutic strategies.